SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10048	Companies
204959	Keywords
135209	Articles
108668	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/09/2025 at 23:09, 9 months 8 days ago

Sanofi: Information concerning the total number of voting rights and shares - May 2025
Sanofi discloses total voting rights and shares information in compliance with French regulations. Details available on Sanofi's investor relations website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 06/09/2025 at 07:05, 9 months 9 days ago

Sanofi prepares early distribution of Beyfortus to counter RSV

Production Sanofi AstraZeneca VRS Beyfortus
PRESS RELEASE

published on 06/09/2025 at 07:00, 9 months 9 days ago

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season, ensuring broad availability and high efficacy for infants

Healthcare Sanofi Vaccine RSV Beyfortus
BRIEF

published on 06/06/2025 at 20:27, 9 months 11 days ago

Sanofi Discloses Repurchase of Own Shares in Early June 2025

Share Repurchase XPAR Market Stock Transaction 2025 Sanofi
PRESS RELEASE

published on 06/06/2025 at 20:22, 9 months 11 days ago

Sanofi: Disclosure of trading in own shares
Sanofi discloses its trading in own shares from 02 June 2025 to 06 June 2025, repurchasing a total of 105,316 shares at an average price of 86.91 EUR per share on XPAR market

Trading Own Shares XPAR Repurchases Sanofi
BRIEF

published on 06/02/2025 at 07:05, 9 months 16 days ago

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

Rare Diseases Sanofi Acquisition Blueprint Medicines Immunology Pipeline Systemic Mastocytosis
PRESS RELEASE

published on 06/02/2025 at 07:00, 9 months 16 days ago

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease. Acquisition includes Ayvakit/Ayvakyt for systemic mastocytosis and a promising pipeline in immunology

Acquisition Sanofi Rare Diseases Blueprint Medicines Immunological Disease
BRIEF

published on 05/30/2025 at 07:05, 9 months 19 days ago

Itepekimab Reaches Primary Endpoint in COPD Phase 3 Study

Sanofi COPD Regeneron Itepekimab AERIFY-1
PRESS RELEASE

published on 05/30/2025 at 07:00, 9 months 19 days ago

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met primary endpoint in AERIFY-1 study for COPD, with significant reduction in exacerbations. AERIFY-2 did not meet endpoint. Sanofi and Regeneron assessing data for next steps

Sanofi COPD Regeneron Itepekimab AERIFY-1
BRIEF

published on 05/29/2025 at 14:35, 9 months 19 days ago

Positive impact of Beyfortus on hospitalizations due to RSV

Public Health Efficiency Beyfortus VRS Hospitalizations Childhood Vaccination

Accesswire

Published on 03/18/2026 at 13:30, 17 minutes ago

Predictiv AI Launches AGORACOM Marketing Program and Engages Venture Liquidity Partners for Market Making
Published on 03/18/2026 at 13:30, 17 minutes ago

Ameriwest Critical Metals Secures 100% Ownership of Xeno Rare Earth Project as Yttrium Gains Strategic Focus
Published on 03/18/2026 at 12:30, 1 hour 17 minutes ago

Nextech3D.ai Division Achieves Profitability, Signaling Operating Leverage, Margin Expansion and Accelerating Enterprise Momentum
Published on 03/18/2026 at 12:05, 1 hour 42 minutes ago

PEL87 Extension Granted
Published on 03/18/2026 at 12:00, 1 hour 47 minutes ago

North Shore to List on the OTCQB

View all ACCESSWIRE

EQS Group

Published on 03/18/2026 at 12:48, 59 minutes ago

Conference call for investors and analysts on the annual results 2025
Published on 03/18/2026 at 12:00, 1 hour 47 minutes ago

Nebius Group announces pricing of upsized private offering of $4.0 billion of convertible senior notes
Published on 03/18/2026 at 11:42, 2 hours 5 minutes ago

OHB wins EUR 248 million contract for satellite constellation to monitor the Arctic
Published on 03/18/2026 at 11:27, 2 hours 19 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 03/18/2026 at 11:21, 2 hours 25 minutes ago

Amundi Physical Metals plc: Final Terms

Les Echos

Published on 03/18/2026 at 07:00, 6 hours 47 minutes ago

Mersen: A resilient performance in 2025, return to growth expected in 2026
Published on 03/17/2026 at 07:00, 1 day 6 hours ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 19 hours ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 19 hours ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 19 hours ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026

View all LES ECHOS COMFI WIRE